<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To investigate the possibility that activated protein C (APC) resistance due to the factor V could be an important predisposing factor in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>), we have retrospectively examined the prevalence of APC resistance with protein C, protein S and <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> patients (&lt; or = 50 years) admitted to our hospital over the past 7 years </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-seven patients were enrolled in the study </plain></SENT>
<SENT sid="2" pm="."><plain>We divided the patients into two groups, <z:chebi fb="8" ids="10033">warfarin</z:chebi> group (group A) and a non-<z:chebi fb="8" ids="10033">warfarin</z:chebi> group (group B) </plain></SENT>
<SENT sid="3" pm="."><plain>APC resistance is defined as when the APC ratio is below or equal to the cut-off value 2 </plain></SENT>
<SENT sid="4" pm="."><plain>APC resistance was not detected in either group </plain></SENT>
<SENT sid="5" pm="."><plain>The prevalence of an APC ratio below or equal to 2.5 was 16.7% (1 case) in group A and 24.4% (10 cases) in group B </plain></SENT>
<SENT sid="6" pm="."><plain>The prevalence of <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo> was 5.0% (2 cases) in group B </plain></SENT>
<SENT sid="7" pm="."><plain>Two cases (5.0%) in group B had <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0001976'>Antithrombin III deficiency</z:hpo> was not detected in either group </plain></SENT>
<SENT sid="9" pm="."><plain>The prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome measured by APTT was 40.4% (19 cases) </plain></SENT>
<SENT sid="10" pm="."><plain>We compared the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> patients with 97 healthy volunteers (&lt; or = 50 years old) without any <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> or <z:hpo ids='HP_0001892'>bleeding tendency</z:hpo> in their past history </plain></SENT>
<SENT sid="11" pm="."><plain>No significant difference were found between these groups and the volunteers </plain></SENT>
<SENT sid="12" pm="."><plain>APC resistance is a major cause of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in Europe and the United States, while in Japan it is believed to be a minor cause of arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
</text></document>